Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 6:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sarcoidosis, Cardiac Clear all

Conditions: Cardiac Sarcoidosis
Interventions: 11C-PBR PET; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Sarcoidosis
Interventions: Indium-111 Pentreotide, Gallium-68 DOTATATE; Drug
Lead sponsor: Marcelo F. Di Carli, MD, FACC; Other
Eligibility: 18 Years to 90 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiac Sarcoidosis
Interventions: Rilonacept; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Baltimore, Maryland • Rochester, Minnesota

Conditions: Cardiac Sarcoidosis
Interventions: Anakinra; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Richmond, Virginia

Conditions: Cardiac Sarcoidosis
Interventions: Gallium-68 DOTATATE; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Cardiac Sarcoidosis, Becker Muscular Dystrophy, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
Interventions: Hyperpolarized 13C-Pyruvate; Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cardiac Sarcoidosis, Myocardial Inflammation
Interventions: 18F-FSPG; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cardiac Sarcoidosis
Interventions: Sotagliflozin; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cardiac Sarcoidosis
Interventions: hybrid PET/MRI; Diagnostic Test
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cardiac Sarcoidosis
Interventions: Baricitinib (LY3009104) 4 mg; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Cardiac Sarcoidosis, Sarcoidosis of the Heart, Sarcoidosis With Myocarditis, Sarcoidosis, Cardiac
Interventions: Exosome Analysis; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
Interventions: Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™, STEEN Solution™; Procedure · Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 15 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Cardiac Failure, Coronary Artery Disease, Sarcoidosis, Amyloidosis, Lupus, Myocarditis, Drug Toxicity
Interventions: Diagnostic Test: Myostrain; Procedure
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: Not listed
Enrollment: 19 participants
Timeline: 2019
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Sarcoidosis
Interventions: Fluorodeoxyglucose, Rubidium, FDG-PET/CT with Rb82 Myocardial Perfusion Imaging; Drug · Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cardiac Sarcoidosis
Interventions: 68Ga-DOTATATE PET/CT, 18FDG PET/CT scan, 13NH3 PET/CT scan; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sarcoidosis, Cardiac Sarcoidosis, Boeck's Disease, Besnier-Boeck Disease
Interventions: Enhanced Screening Protocol for Cardiac Sarcoidosis., Routine Screening for Suspected Cardiac Sarcoidosis; Diagnostic Test
Lead sponsor: Foundation for Sarcoidosis Research; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 10
States / cities: Denver, Colorado • Chicago, Illinois • Iowa City, Iowa + 6 more

Conditions: Sarcoidosis, Cardiac
Interventions: Namilumab; Drug
Lead sponsor: Kinevant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 12
States / cities: Palo Alto, California • Denver, Colorado • New Haven, Connecticut + 9 more

Conditions: Cardiac Sarcoidosis
Interventions: Tc 99m tilmanocept; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Arrhythmogenic Right Ventricular Cardiomyopathy, Cardiomyopathies, Heart Diseases, Cardiovascular Diseases, Sudden Cardiac Arrest, Sudden Cardiac Death, Arrhythmogenic Right Ventricular Dysplasia, Arrhythmogenic Ventricular Cardiomyopathy, Familial Dilated Cardiomyopathy, Cardiovascular Abnormalities, Sarcoidosis, Cardiac Arrhythmia, Cardiac Sarcoidosis, Myocarditis, Inflammatory Cardiomyopathy, Ventricular Tachycardia, Right Ventricular Outflow Tract Ventricular Tachycardia
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sarcoidosis of the Heart, Cardiomyopathy
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Sarcoidosis, Precapillary Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Inhaled Treprostinil; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cardiac Sarcoidosis, Sarcoidosis
Interventions: Prednisone or Prednisolone, Methotrexate; Drug
Lead sponsor: Ottawa Heart Institute Research Corporation; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 9
States / cities: New Haven, Connecticut • Boston, Massachusetts • Ann Arbor, Michigan + 6 more

Conditions: Sarcoidosis With Myocarditis, Sarcoidosis, Healthy, ST Elevation Myocardial Infarction
Interventions: cell free DNA; Diagnostic Test
Lead sponsor: Nabeel Hamzeh; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Sarcoidosis
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 27,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2032
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Non-Invasive Characterization in Cardiac Sarcoidosis

Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis

Rilonacept in Subjects With Cardiac Sarcoidosis

Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis

PET Imaging in Patients With Suspected Cardiac Sarcoidosis

UTSW HP [13-C] Pyruvate Injection in HCM

18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation

Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression

Feasibility and Accuracy of Hybrid Magnetic Resonance and Positron Emission Tomography With 18F-Fluorodeoxyglucose in Diagnosing Cardiac Sarcoidosis

A Trial of Baricitinib in Patients With Cardiac Sarcoidosis

Exosome-based Omic Signatures of Disease Activity in Cardiac Sarcoidosis (EXODACS)

Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability

Evaluation of MyoStrain™ in Clinical Practice

Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82

d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis

Routine Cardiac Screening in Sarcoidosis Patients

A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis

Repurposing Tilmanocept for Cardiac Sarcoidosis

Mayo AVC Registry and Biobank

Implantable Cardiac Defibrillators for the Prevention of Sudden Death in Patients With Cardiac Sarcoidosis

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

Cardiac Sarcoidosis Randomized Trial

Cell Free DNA in Cardiac Sarcoidosis

Prognostic Value of Clinical Cardiovascular MRI